The report is based on in-depth qualitative research in countries along the Eastern and Central Mediterranean routes. It focuses on Iraqi and Nigerian migrants as case studies, as Nigeria is the number one country of origin for migrants travelling along the Central Mediterranean route. Iraqis repres...ent the third biggest group of migrants who travelled along the Eastern Mediterranean route in 2016.
more
With the increase in frequency of disasters, there is a need to improve early warning systems (EWS) for EA to reduce the risks faced by children and their families. As a consequence, the term early warning, early action (EWEA) has become increasingly common among those responding to slow-onset disas...ters.
more
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
Learning from the Use of Data, Information, and Digital Technologies in the West Africa Ebola Outbreak Response
Int J Vaccines Vaccin 2016, 2(1): 00018, January 29, 2016
10–11 May 2016, Catania, Italy
This exploratory study carried out in Coastal Kenya by TUM - funded and supported by CBM – draws attention to monetisable social factors in the measurement of impacts of livelihood promotion. When NGOs in development cooperation try to capture the effects of livelihood promotion programmes for the... target group (e.g. persons with disabilities) and their families, it is not enough to only look at the individual’s income or consider common business economics measurements (like Return on Investment) but to look more widely on the changes in the Quality of Life. This study tried to apply the so called Social Return on Investment (SROI) approach in the field of livelihood promotion. For this goal a general formula was developed and field-tested to account for a broad range of (social) impacts.
more
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...men characteristics corresponding to the needs of end-users.
more
SIAPS Technical Report. This report summarizes key accomplishments and lessons learned in implementing SIAPS’ approach to improving IPC practices in four countries: South Africa, Namibia, Jordan, and Ethiopia. All activities address SIAPS’s overall objective to build or enhance national and faci...lity capacity to develop, implement, and monitor IPC programs by focusing on the principles of health systems strengthening.
more
Interim Guidance.
A number of medical problems have been reported in survivors, including mental health issues. Ebola virus may persist in some body fluids, including semen. Ebola survivors need comprehensive support for the medical and psychosocial challenges they face and also to minimize the ...risk of continued Ebola virus transmission. WHO has developed this document to guide health services on how to provide quality care to survivors of Ebola virus disease
more
PLoSONE 12(9):e0184986.https://doi.org/10.1371/journal.pone.0184986
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more
Patients with retreatment tuberculosis (TB) represent those
who have been treated previously for onemonth ormorewith
anti-TB drugs and who have been diagnosed once again with
the disease.These patientsmainly include relapses, treatment
after failure, or loss to follow-up on a first-line treatmen...t
regimen [1]. The number of these patients is not negligible.
In 2014, of the 6.3 million TB cases that were notified
by National TB Programmes (NTPs) to the World Health
Organization (WHO), approximately 700,000 patients were
already previously treated
more